Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Shell PLC (SHEL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Shell PLC — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while Shell PLC trades at $82.1 (market cap $220.29B). The key difference: Shell PLC is far larger — about 49.1× ACADIA Pharmaceuticals Inc.'s market cap, and Shell PLC pays a 3.81% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | SHEL | |
|---|---|---|
Market Cap | $4.49B | $220.29B |
Sector | Health | Energy |
52-Week High | $28.06 | $94.15 |
52-Week Low | $20.06 | $70.28 |
Enterprise Value | $3.69B | $272.82B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Shell (SHEL) trades at $81.99, up 5.09% on the day, with strong analyst support showing 69% buy ratings and a $112.10 consensus price target. The stock shows attractive valuation metrics with P/E of 12.17 and P/S of 0.86, while recent Q1 2026 earnings beat expectations. However, technical indicators signal bearish momentum despite positive news about stronger gas trading performance and improved refining margins ahead of Q2 results.
Shell presents a compelling value opportunity with solid profitability (7.01% net margin) and strong cash flow generation, though faces headwinds from declining revenue trends and geopolitical risks affecting production. The company's strategic focus on LNG growth and portfolio optimization supports long-term prospects, but investors should monitor execution risks and oil price volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
